Login to Your Account

Other News To Note

Thursday, September 20, 2012

• Intellect Neurosciences Inc., of New York, and MRC Technology, of London, said they completed humanization of 82E1, a mouse monoclonal antibody to create a high-affinity stabilized IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription